ImmunityBio’s glioblastoma regimen boosts survival in mid-stage study
ImmunityBio’s immunotherapy combination regimen has demonstrated its early potential during a mid-stage trial in patients with glioblastoma and severe lymphopenia.…
News
CVRx’s stock up as heart failure device to be trialled in expanded patient group
Sanofi’s Dupixent successor heads to regulators after Phase III success
IGC Pharma adds New York site for Alzheimer’s disease trial
Corcept’s stock up as relacorilant meets OS goal in Phase III ovarian cancer trial
US set to officially exit WHO in culmination of Trump’s domestic push
Kardium unveils further pivotal trial results for Globe PFA system
BBH and PhaseWell partner for neuropsychiatric trials
